|
[1]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.
|
|
[2]World Health Organization.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[EB/OL]. (2016-04) [2017-05-25]http://apps.who.int/iris/bitstream/10665/204452/1/WHO_HIV_2016.01_eng.pdf.
|
|
[3]EL-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576.
|
|
[4]HUANG YW, YANG SS, FU SC, et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with newonset diabetes:a nationwide cohort study[J].Hepatology, 2014, 60 (3) :807-814.
|
|
[5]BUNCHORNTAVAKUL C, MANEERATTANAPORN M, CHAVALIT-DHAMRONG D.Management of patients with hepatitis C infection and renal disease[J].World J Hepatol, 2015, 7 (2) :213-225.
|
|
[6]ASSELAH T, MARCELLIN P.Direct acting antivirals for the treatment of chronic hepatitis C:one pill a day for tomorrow[J].Liver Int, 2012, 32 (Suppl 1) :88-102.
|
|
[7]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
|
[8]LAWITZ E, GANE EJ.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 369 (7) :678-679.
|
|
[9]SHIFFMAN ML, SUTER F, BACON BR, et al.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[J].N Engl J Med, 2007, 357 (2) :124-134.
|
|
[10]SAXENA V, NYBERG L, PAULY M, et al.Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis[J].Hepatology, 2015, 62 (3) :715-725.
|
|
[11]BARTENSCHLAGER R, LOHMANN V.Replication of hepatitis Cvirus[J].J Gen Virol, 2000, 81 (Pt 7) :1631-1648.
|
|
[12]MANNS M, POL S, JACOBSON IM, et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational, phase 3, multicohort study[J].Lancet, 2014, 384 (9954) :1597-1605.
|
|
[13]Mc PHEE F, SUZUKI Y, TOYOTA J, et al.High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5Apolymorphisms[J].Adv Ther, 2015, 32 (7) :637-649.
|
|
[14]ZEUZEM S, MIZOKAMI M, PIANKO S, et al.NS5A resistanceassociated substitutions in patients with genotype 1 hepatitis C virus:prevalence and effect on treatment outcome[J].J Hepatology, 2017, 66 (5) :910-918.
|
|
[15]LAWITZ E, MATUSOW G, DEJESUS E, et al.Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis:a phase 3 study (OPTIMIST-2) [J].Hepatology, 2016, 64 (2) :360-369.
|
|
[16]MANNS MP, Mc HUTCHISON JG, GORDON SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J].Lancet, 2001, 358 (9286) :958-965.
|
|
[17]ANDREONE P, COLOMBO MG, ENEJOSA JV, et al.ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97%and 100%sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection[J].Gastroenterology, 2014, 147 (2) :359-365, e1.
|
|
[18]FELD JJ, KOWDLEY KV, COAKLEY E, et al.Treatment of HCVwith ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].NEngl J Med, 2014, 370 (17) :1594-1603.
|
|
[19]KOWDLEY KV, GORDON SC, REDDY KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med, 2014, 370 (20) :1879-1888.
|
|
[20]JACOBSON IM, GORDON SC, KOWDLEY KV, et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med, 2013, 368 (20) :1867-1877.
|
|
[21]HULL MW, YOSHIDA EM, MONTANER JS.Update on current evidence for hepatitis C therapeutic options in HCV mono-infected patients[J].Curr Infect Dis Rep, 2016, 18 (7) :22.
|
|
[22]ZEUZEM S, DUSHEIKO GM, SALUPERE R, et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med, 2014, 370 (21) :1993-2001.
|
|
[23]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.
|
|
[24]FELD JJ, JACOBSON IM, HEZODE C, et al.Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection[J].N Engl J Med, 2015, 373 (27) :2599-2607.
|
|
[25]FOSTER GR, AFDHAL N, ROBERTS SK, et al.Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection[J].N Engl J Med, 2015, 373 (27) :2608-2617.
|
|
[26]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[27]MAASOUMY B, MANNS MP.Optimal treatment with boceprevir for chronic HCV infection[J].Liver Int, 2013, 33 (Suppl 1) :14-22.
|
|
[28]JESUDIAN AB, JACOBSON IM.Optimal treatment with telaprevir for chronic HCV infection[J].Liver Int, 2013, 33 (Suppl 1) :3-13.
|
|
[29]MAASOUMY B, VERMEHREN J, WELKER MW, et al.Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens[J].J Hepatol, 2016, 65 (3) :473-482.
|
|
[30]ZHU Y, CHEN S.Antiviral treatment of hepatitis C virus infection and factors affecting efficacy[J].World J Gastroenterol, 2013, 19 (47) :8963-8973.
|
|
[31]SOFIA MJ.Nucleotide prodrugs for the treatment of HCV infection[J].Adv Pharmacol, 2013, 67:39-73.
|
|
[32]AL MARZOOQI SH, FELD JJ.Sorting out cirrhosis:mechanisms of non-response to hepatitis C therapy[J].Liver Int, 2015, 35 (8) :1923-1933.
|
|
[33]SCHOOLEY RT.The fragile relationship between hepatitis C virus and its human host[J].Top Antivir Med, 2014, 21 (5) :148-151.
|
|
[34]POORDAD F, HEZODE C, TRINH R, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis[J].N Engl J Med, 2014, 370 (21) :1973-1982.
|
|
[35]LAUFFENBURGER JC, MAYER CL, HAWKE RL, et al.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database:high utilization of drugs with interaction potential[J].Eur J Gastroenterol Hepatol, 2014, 26 (10) :1073-1082.
|
|
[36]KISER JJ, FLEXNER C.Direct-acting antiviral agents for hepatitis Cvirus infection[J].Annu Rev Pharmacol Toxicol, 2013, 53:427-449.
|
|
[37]KONDILI LA, GAETA GB, IELUZZI D, et al.Real-life data on potential drug-drug interactions in patients with chronic hepatitis Cviral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study[J].PLo S One, 2017, 12 (2) :e0172159.
|
|
[38]SORIANO V, LABARGA P, BARREIRO P, et al.Drug interactions with new hepatitis C oral drugs[J].Expert Opin Drug Metab Toxicol, 2015, 11 (3) :333-341.
|
|
[39]HUNDEMER GL, SISE ME, WISOCKY J, et al.Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency[J].Infect Dis (Lond) , 2015, 47 (12) :924-929.
|
|
[40]PETERSEN T, TOWNSEND K, GORDON LA, et al.High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study[J].Hepatol Int, 2016, 10 (2) :310-319.
|
|
[41]WYLES D, POCKROS P, MORELLI G, et al.Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens[J].Hepatology, 2015, 61 (6) :1793-1797.
|
DownLoad: